XML 45 R32.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Summary Of Significant Accounting Policies - Additional Information (Detail) $ / shares in Units, € in Thousands |  |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 28, 2014 USD ($) | Sep. 03, 2014 USD ($) | Jan. 30, 2014 USD ($) | Sep. 04, 2013 USD ($) | Jan. 22, 2013 USD ($) | Apr. 06, 2007 shares | Sep. 30, 2014 USD ($) | Dec. 31, 2015 USD ($) Investment $ / shares shares | Sep. 30, 2015 USD ($) | Jun. 30, 2015 USD ($) | Mar. 31, 2015 USD ($) | Dec. 31, 2014 USD ($) $ / shares shares | Sep. 30, 2014 USD ($) | Jun. 30, 2014 USD ($) | Mar. 31, 2014 USD ($) | Dec. 31, 2015 USD ($) Investment Segment $ / shares shares | Dec. 31, 2015 EUR (€) Segment shares | Dec. 31, 2014 USD ($) $ / shares shares | Dec. 31, 2013 USD ($) $ / shares shares
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares purchased through issuance of warrants | shares |  |  |  |  |  | 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant term |  |  |  |  |  | 7 years |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,115,000 |  |  |
Non-refundable up-front payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,000,000 |  |  |
Payment to be received upon signing of agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 125,675 |  |  |
Revenue recognized under revenue recognition, up front payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,000,000 |  |  |  |
Royalty and other revenue |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000 | $ 125,000 |  | 1,991,000 |  |  | $ 3,117,000 | $ 20,687,000
Percentage of royalty revenue, remittance to the University of Michigan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15.00%
Cost of royalty revenue |  |  |  |  |  |  |  | $ 0 | $ 0 | $ 0 | $ 0 | 0 | 0 | $ 0 | 0 |  |  |  | $ 2,682,000
Revenue from sponsored research and development projects |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0 |  | 0 | 803,000
Long-term marketable securities, minimum original maturity term |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 year | 1 year |  |
Marketable securities, average remaining contractual maturity period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 months 24 days | 5 months 24 days |  |
Number of debt securities in unrealized loss positions | Investment |  |  |  |  |  |  |  | 34 |  |  |  |  |  |  |  | 34 |  |  |
Debt securities in unrealized loss positions, total unrealized loss |  |  |  |  |  |  |  | $ 19,000 |  |  |  |  |  |  |  | $ 19,000 |  |  |
Debt securities in unrealized loss positions, total fair market value |  |  |  |  |  |  |  | 12,520,000 |  |  |  |  |  |  |  | 12,520,000 |  |  |
Credit risk |  |  |  |  |  |  |  | 0 |  |  |  |  |  |  |  | 0 |  |  |
Gain (loss) on investments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  | 0 | 0
Fair value of other assets |  |  |  |  |  |  |  | 0 |  |  |  |  |  |  |  | 0 |  |  |
Fair value of other liabilities |  |  |  |  |  |  |  | 0 |  |  |  |  |  |  |  | 0 |  |  |
Increase to milestone payment |  |  |  |  |  |  |  | 1,969,000 | $ 233,000 | $ 768,000 | $ 1,112,000 | 1,945,000 | $ 10,000 | $ 18,000 | 98,000 | 4,083,000 |  | 2,072,000 | $ 91,000
Payment of contingent considerations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 99,000 |  |  |
Reserves for excess and obsolete inventory |  |  |  |  |  |  |  | $ 343,000 |  |  |  | $ 78,000 |  |  |  | $ 343,000 |  | $ 78,000 |
Stock options, outstanding | shares |  |  |  |  |  |  |  | 1,240,935 |  |  |  | 1,225,117 |  |  |  | 1,240,935 |  | 1,225,117 | 1,610,988
Stock options, weighted average exercise price | $ / shares |  |  |  |  |  |  |  | $ 10.44 |  |  |  | $ 8.31 |  |  |  | $ 10.44 |  | $ 8.31 | $ 5.07
Common stock excluded from calculation of diluted earnings per share | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 196,209 | 196,209 | 307,475 | 187,000
Number of operating segment | Segment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 | 1 |  |
Long Lived Assets |  |  |  |  |  |  |  | $ 42,985,000 |  |  |  | $ 47,348,000 |  |  |  | $ 42,985,000 |  | $ 47,348,000 |
Goodwill impairment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  | 0 | $ 0
Amortization expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,600,000 |  | $ 1,425,000 | 1,022,000
Employee Stock Option | Awards Granted to Non-Executive Level Employees |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated forfeiture rates |  |  |  |  |  |  |  | 8.00% |  |  |  | 8.00% |  |  |  | 8.00% |  | 8.00% |
Employee Stock Option | Awards Granted to Executive Level Employees |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated forfeiture rates |  |  |  |  |  |  |  | 3.00% |  |  |  | 3.00% |  |  |  | 3.00% |  | 3.00% |
Non-Employee Directors |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated forfeiture rates |  |  |  |  |  |  |  |  |  |  |  | 0.00% |  |  |  |  |  | 0.00% |
Singapore |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Long Lived Assets |  |  |  |  |  |  |  | $ 0 |  |  |  | $ 0 |  |  |  | $ 0 |  | $ 0 |
Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Short-term marketable securities, minimum original maturity term |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 90 days | 90 days |  |
Licensing Agreements | Scripps Research Institute |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License Agreement, initial license fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 300,000 |  |  |
Total future milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,300,000 |  |  |
Common stock, shares issued | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 87,464 | 87,464 |  |
Common stock, shares issued value |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 300,000 |  |  |
Common stock, shares purchased through issuance of warrants | shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150,000 |
Warrant term |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7 years |
Technology Transfer |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0 |  |  |  |
Estimated selling price |  |  |  |  |  |  |  | 300,000 |  |  |  |  |  |  |  | 300,000 |  |  |
Consideration allocated to transaction |  |  |  |  |  |  |  | 11,000 |  |  |  |  |  |  |  | 11,000 |  |  |
Royalty and other revenue |  |  |  |  |  |  | $ 125,675 |  |  |  |  |  |  |  |  |  |  |  |
Refine Technology, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase to milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,048,000 |  |  |
Refine Technology, LLC | Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment of contingent considerations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000,000 |  |  |
Bio Flash | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 110,000 |  |  |
Novozymes Biopharma DK A/S Sweden Ab | Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment of contingent considerations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 29,000 | € 25 |  |
Non-software License Arrangement | Pfizer Incorporation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received under license agreement |  |  |  |  | $ 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment | $ 1,000,000 |  |  | $ 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical Development |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 60,000,000 |  |  |
Potential milestone payments to be received |  |  |  |  |  |  |  | 60,000,000 |  |  |  |  |  |  |  | $ 60,000,000 |  |  |
Royalty term |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 years | 10 years |  |
Initial Commercial Sales |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments to be received |  |  |  |  |  |  |  | $ 100,000,000 |  |  |  |  |  |  |  | $ 100,000,000 |  |  |
BioMarin Pharmaceutical, Inc. | Asset Purchase Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received under license agreement |  |  | $ 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments to be received |  |  |  |  |  |  |  |  |  |  |  | $ 160,000,000 |  |  |  |  |  | $ 160,000,000 |
Provision for refund |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,100,000 |
BioMarin Pharmaceutical, Inc. | Technology Transfer Payments | Asset Purchase Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment |  | $ 125,675 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
BioMarin Pharmaceutical, Inc. | Clinical Development | Asset Purchase Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage relate to clinical development from Milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 37.00% |
BioMarin Pharmaceutical, Inc. | Initial Commercial Sales | Asset Purchase Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage relate to clinical development from Milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 63.00% |
Orencia Royalties from Bristol |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty and other revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 17,881,000
Cost of royalty revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,682,000

X
- Definition Amount To Be Received Upon Completion Of Transfer + References No definition available. + Details
Name: | rgen_AmountToBeReceivedUponCompletionOfTransfer
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Consideration Allocated To Transaction Rights + References No definition available. + Details
Name: | rgen_ConsiderationAllocatedToTransactionRights
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Impact Of Credit Risk On Fair Value Of Derivatives + References No definition available. + Details
Name: | rgen_ImpactOfCreditRiskOnFairValueOfDerivatives
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Long Lived Assets Held for sale, Estimated Selling Cost + References No definition available. + Details
Name: | rgen_LongLivedAssetsHeldForSaleEstimatedSellingCost
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Long Term Marketable Securities Maturities Term, Minimum + References No definition available. + Details
Name: | rgen_LongTermMarketableSecuritiesMaturitiesTermMinimum
Namespace Prefix: | rgen_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Marketable Debt Securities Weighted Average Remaining Maturity Period + References No definition available. + Details
Name: | rgen_MarketableDebtSecuritiesWeightedAverageRemainingMaturityPeriod
Namespace Prefix: | rgen_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Non Contingent Consideration Being Recognized As Revenue Over Estimated Period Of Performance + References No definition available. + Details
Name: | rgen_NonContingentConsiderationBeingRecognizedAsRevenueOverEstimatedPeriodOfPerformance
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Nonrefundable Upfront Cash Payment Under Collaborations Agreement + References No definition available. + Details
Name: | rgen_NonrefundableUpfrontCashPaymentUnderCollaborationsAgreement
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage Of Future Milestone Payments + References No definition available. + Details
Name: | rgen_PercentageOfFutureMilestonePayments
Namespace Prefix: | rgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of Shares Subject to Forfeiture + References No definition available. + Details
Name: | rgen_PercentageOfSharesSubjectToForfeiture
Namespace Prefix: | rgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Potential Additional Milestone Payments Associated With Potential Regulatory Approvals + References No definition available. + Details
Name: | rgen_PotentialAdditionalMilestonePaymentsAssociatedWithPotentialRegulatoryApprovals
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential Milestone Payment + References No definition available. + Details
Name: | rgen_PotentialMilestonePayment
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Provision For Wholesale Refunds + References No definition available. + Details
Name: | rgen_ProvisionForWholesaleRefunds
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty Contractual Term + References No definition available. + Details
Name: | rgen_RoyaltyContractualTerm
Namespace Prefix: | rgen_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty Payment Rate + References No definition available. + Details
Name: | rgen_RoyaltyPaymentRate
Namespace Prefix: | rgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Short Term Marketable Securities Maturities Period + References No definition available. + Details
Name: | rgen_ShortTermMarketableSecuritiesMaturitiesPeriod
Namespace Prefix: | rgen_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Stock Issued During Period, Shares, Common Stock Warrants + References No definition available. + Details
Name: | rgen_StockIssuedDuringPeriodSharesCommonStockWarrants
Namespace Prefix: | rgen_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary Of Significant Accounting Policies [Line Items] + References No definition available. + Details
Name: | rgen_SummaryOfSignificantAccountingPoliciesLineItems
Namespace Prefix: | rgen_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Warrant Term + References No definition available. + Details
Name: | rgen_WarrantTerm
Namespace Prefix: | rgen_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Antidilution -URI http://asc.fasb.org/extlink&oid=6505113 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Diluted Earnings Per Share -URI http://asc.fasb.org/extlink&oid=6510752 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Contingent Stock Agreement -URI http://asc.fasb.org/extlink&oid=6508534 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.10-17) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 18 -Article 5 + Details
Name: | us-gaap_AssetsNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale in a continuous loss position. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27337-111563 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 6 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563 + Details
Name: | us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition This item represents the aggregate fair value of investments in debt and equity securities in an unrealized loss position which are categorized neither as held-to-maturity nor trading securities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 6 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563 + Details
Name: | us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of investment positions in available-for-sale investments in a continuous unrealized loss position for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 6 -Subparagraph (b)(3) -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563 + Details
Name: | us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueAdditions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty expense incurred and are directly related to goods produced and sold and services rendered during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_DirectOperatingCostRoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any gains (losses) realized during the period from the sale of investments accounted for under the cost method of accounting and losses recognized for other than temporary impairments (OTTI) of the subject investments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (c)-(e) -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7(c),9(a)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27405-111563 + Details
Name: | us-gaap_GainLossOnInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13777-109266 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 + Details
Name: | us-gaap_GoodwillImpairmentLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of valuation reserve for inventory. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.BB) -URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-09) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 35 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312 + Details
Name: | us-gaap_InventoryValuationReserves
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + References No definition available. + Details
Name: | us-gaap_NumberOfOperatingSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value portion of other assets. + References No definition available. + Details
Name: | us-gaap_OtherAssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fair value portion of other liabilities. + References No definition available. + Details
Name: | us-gaap_OtherLiabilitiesFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of cash paid for royalties during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585 + Details
Name: | us-gaap_PaymentsForRoyalties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow for financing costs associated with business combinations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585 + Details
Name: | us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=51671726&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_RoyaltyRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of options outstanding, including both vested and non-vested options. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i)-(ii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodValueIssuedForServices
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TitleOfIndividualAxis=rgen_NonExecutiveMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=rgen_NonEmployeeDirectorStockOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_SG
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=rgen_ScrippsResearchInstituteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rgen_TechnologyTransferMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=rgen_RefineTechnologyLimitedLiabilityCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=rgen_MilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=rgen_BioFlashPartnersLimitedLiabilityCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=rgen_NovozymesBiopharmaSwedenAbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_NonsoftwareLicenseArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=rgen_PfizerIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rgen_ClinicalResearchMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rgen_FirstCommercialSaleMilestoneEventsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=rgen_BiomarinPharmaceuticalIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=rgen_AssetPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rgen_TechnologyTransferPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=rgen_BristolMyersSquibbCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |